Flexible MoS2-Embedded Human Serum Albumin Hollow Nanocapsules with Long Circulation Times and High Targeting Ability for Efficient Tumor Ablation
Flexible MoS2-Embedded Human Serum Albumin Hollow Nanocapsules with Long Circulation Times and High Targeting Ability for Efficient Tumor Ablation
复制标题
柔性MoS2包埋人血清白蛋白中空纳米胶囊，具有长循环时间和高靶向能力，可有效消融肿瘤
DOI：
10.1002/adfm.201804081
复制
发表时间：
2018-11-07
影响因子：
19
通讯作者：
Zhu, Jiang
中科院分区：
文献类型：
--
作者：
Xu, Chaoli;Teng, Zhaogang;Zhu, Jiang
本论文采用硬核辅助逐层包覆的方法成功制备了MoS2包埋的人血清白蛋白中空纳米胶囊(MoS2/HSA)。制备的中空MoS2/HSA纳米胶囊具有均匀的尺寸(280 Nm)、较大的中空空腔、较低的杨氏模数(222+/-20 Mpa)、优异的光热转化能力和对阿霉素的高载药量(27wt%)。柔性中空MoS2/HSA纳米胶囊由于其柔性的性质和HSA的靶向性，显著提高了细胞对乳腺癌细胞的摄取效率。体内实验表明，柔性MoS2/HSA可以减少吞噬功能，有效改善血液滞留和肿瘤聚集。体外和体内实验表明，基于柔性MoS2/HSA的纳米平台通过光热和化学治疗的协同作用有效地消融了乳腺癌细胞。
Herein, MoS2-embedded human serum albumin hollow nanocapsules (denoted MoS2/HSA) are successfully prepared via a hard-core-assisted layer-by-layer coating approach. The hollow MoS2/HSA nanocapsules possess an uniform size (280 nm), a larger hollow cavity, a low Young's modulus (222 +/- 20 MPa), excellent photothermal conversion ability, and a high drug loading capacity for doxorubicin (27 wt%). The flexible hollow MoS2/HSA nanocapsules exhibit significantly enhanced cellular uptake efficiency against breast cancer cells duo to their flexible property and targeting ability of HSA. In vivo experiments show that the flexible MoS2/HSA could reduce phagocytosis and effectively improve blood persistence and tumor accumulation. In vitro and in vivo experiments have demonstrated that the flexible MoS2/HSA based nanoplatforms effectively ablate breast cancer cells via synergistic photothermal and chemical therapy.